February 5, 2010 — Long-acting injectable olanzapine is effective in providing up to 24 weeks of maintenance treatment for patients with schizophrenia, according to results from a new randomized ...

A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer patients managing nausea and vomiting unrelated to chemotherapy. Olanzapine ...

January 9, 2009 — The road to approval for the long-acting formulation of Eli Lilly’s antipsychotic drug olanzapine (Zyprexa) took a detour recently when the US Food and Drug Administration (FDA) ...

(RTTNews) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first long-acting ...

Olanzapine is an effective antipsychotic medication, but the associated weight gain is the number one cause of discontinuation, explained Adam Simmons, director of clinical program management, ...

In a randomized, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist, ...

Janssen's Risperdal and Astrazeneca's Seroquel Overtake Eli Lilly's Zyprexa as the First-Line Antipsychotics of Choice in the Treatment for Schizophrenia Bristol Meyers Squibb/Otsuka Pharmaceutical's ...

Olanzapine showed superiority vs prochlorperazine for changes in maximum nausea score and quality of life, but not for average nausea. (HealthDay News) — Olanzapine may be better than prochlorperazine ...

Olanzapine, a generic drug used to treat nervous, emotional and mental conditions, also may help patients with advanced cancer successfully manage nausea and vomiting unrelated to chemotherapy. These ...

Chemotherapy-induced nausea and vomiting are among the most distressing side effects of anti-cancer treatment, particularly for those receiving highly emetogenic regimens such as anthracycline plus ...

Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California Teva will host a conference ...